Vitale et al. initially observed that a downregulation of HLA I associated with both TAP1 and TAP2 reduced expression in the majority of primary high-grade BC lesions studied (68%) but not primary low-grade lesions, regardless of the molecular subtype [39] (Figure 1). This evidence concerns the gene TAP2 and breast cancer.